JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (8): 60-63.doi: 10.6040/j.issn.1671-7554.0.2016.199

Previous Articles     Next Articles

Clinical studies on type 2 diabetic patients treated with sitagliptin

PENG Li1, QIANG Ye2, ZHAO Huichen2, CHEN Shihong3, YAO Weidong1, LIU Yuantao2   

  1. 1. Cadres Ward, Jinan Fourth Peoples Hospital, Jinan 250031, Shandong, China;
    2. Department of Endocrinology, Qingdao Municipal Hospital, Qingdao 266011, Shandong, China;
    3. Department of Endocrinology, Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Received:2016-02-29 Online:2016-08-10 Published:2016-08-10

PDF (PC)

759

Abstract: Objective To analyze the factors that affect the efficacy of sitagliptin in the treatment of type 2 diabetic mellitus(T2DM)patients. Methods Clinical data of 86 T2DM patients who treated with sitagliptin during Sept.2012 and June 2014 were collected. According to the levels of fasting C peptide, the patients were divided into two groups: maximum C peptide group(n=12)and minimum C peptide group(n=12). Multiple line regression analysis was performed to analyze the factors that might affect the efficacy of sitagliptin. Results After administration of sitagliptin, there was no significant difference in the decrease of fasting blood glucose(FBG)and 2 h post prandial blood glucose(2h-PBG)between the maximum and minimum C peptide groups(P>0.05). Multiple line regression analysis showed that HbA1c was an independent factor that affected the decrease of FBG; baseline 2h-PBG level was an independent factor that affected the efficacy of sitagliptin on 2h-PBG. Sitagliptin significantly decreased glucose excursion(P<0.05), and reduced episodes of hypoglycemia. Conclusion Sitagliptin decreases both FBG and 2h-PBG. The efficacy of sitagliptin may not entirely depend on C peptide levels. Sitagliptin significantly decreases blood excursion and hypoglycemia.

Key words: Type 2 diabetes mellitus, Sitagliptin, Fasting blood glucose, 2 h post prandial blood glucose

CLC Number: 

  • R574
[1] Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2(non-insulin-dependent)diabetes[J]. Diabetologia, 1986, 29(1): 46-52.
[2] Abraham EJ, Leech CA, Lin JC, et al. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells[J]. Endocrinology, 2002, 143(8): 3152-3161.
[3] Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus[J]. Diabetologia, 2005, 48(6): 1168-1172.
[4] 叶潇, 张倩, 曹瑛, 等. 西格列汀与阿卡波糖治疗新诊断2型糖尿病患者的疗效比较[J]. 中国糖尿病杂志, 2012, 8(20): 619-621. YE Xiao, ZHANG Qian, CAO Ying, et al. Comparison of therapeutic effects of sitagliptin versus acarbose for newly-diagnosed T2DM patients[J]. Chin J Diabetes, 2012, 8(20): 619-621.
[5] Giuseppe D, Pietro DR, Elena F, et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation[J]. Fund Clin Pharmacol, 2014, 28(2): 221-229
[6] Keiji Y. Efficacy of initial basal-supported oral therapy with sitagliptin in untreated type 2 diabetes[J]. Diabetes Ther, 2013, 4(2): 409-416.
[7] Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes[J]. Diabetes, 2006, 55(6): 1695-1704.
[8] Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats[J]. Diabetes, 2003, 52(3): 741-750.
[9] Yuan GY, Jia J, Zhang CL, et al. Safety and effcacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion(CSII)therapy in patients with newly diagnosed type 2 diabetes[J]. Endocrine Journal, 2014, 61(5): 513-521.
[10] Lu J, Zang J, Li H. Impact of three oral antidiabetic drugs on markers of b-Cell function in patients with type 2 diabetes: A meta-analysis[J]. PLoS One, 8(10): e76713. doi:10.1371/journal.pone.0076713.
[11] Gerald HT. Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors[J]. World J Diabetes, 2014, 5(5): 636-650.
[12] Holst JJ. The physiology of glucagon-like peptide 1[J]. Physiol Rev, 2007, 87(4): 1409-1439.
[13] Urd K, Jens JH, Sten M. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual b-Cell function[J]. Diabetes, 2011, 60(5): 1599-1607.
[14] Behme MT, Dupré J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes[J]. BMC Endocr Disord, 2003, 3(1): 3.
[15] Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36)amide in type I diabetic patients[J]. Diabetes Care, 1996, 19(6): 580-586.
[16] Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitorsitagliptinas monotherapy on glycemic control in patients with type 2 diabetes[J]. Diabetes Care, 2006, 29(12): 2632-2637.
[17] Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers[J]. J Clin Endocrinol Metab, 2002, 87(3): 1239-1246.
[18] PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe non-proliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study(PKC-DRS)multicenter randomized clinical trial[J]. Diabetes, 2005, 54(7): 2188-2197.
[1] MENG Xiaomei, HAO Yaping, WANG Liang, YU Xiao, TANG Yuxiao. Correlation between the levels of serum Isthmin1, Gremlin2 and retinopathy in type 2 diabetic patients [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 102-107.
[2] SHEN Lujia, LU Tianwei, GONG Weiming, ZHAO Yansong, WANG Shukang, YUAN Zhongshang. Application of metabolomic risk score in predicting cardiovascular outcomes in patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2025, 63(8): 69-78.
[3] CHEN Yingying, WANG Lu, HU Xifeng, ZHU Gaopei, XUE Fuzhong. A Bayesian network-based risk prediction study of stroke in patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2025, 63(8): 94-102.
[4] LI Jinquan, GAO Meifang, YAN Fei, DONG Ming. Frequency and risk factors of muscle cramp in 136 cases of type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 20-24.
[5] HAN Mei, MENG Weijing, TAO Zikun, YANG Xi, XU Yaqi, MU Huaxia, BU Weixiao, WANG Suzhen, SHI Fuyan. Causal mediation analysis with multiple-mediator of hypertension and depression between type 2 diabetes mellitus and cognitive function based on G-computation [J]. Journal of Shandong University (Health Sciences), 2023, 61(10): 101-108.
[6] LYU Li, JIANG Lu, CHEN Shihong, ZHUANG Xianghua, SONG Yuwen, WANG Dianhui, AN Wenjuan, LI Qian, PAN Zhe. Related factors of osteoporosis in 210 postmenopausal women with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 19-25.
[7] ZHENG Fengjie, SONG Yuwen, SUN Aili, PAN Zhe, WANG Dianhui, LOU Nengjun, LYU Li, ZHUANG Xianghua, CHEN Shihong. Correlation between diabetic peripheral neuropathy and sarcopenia [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 38-44.
[8] LIU Ping, SONG Yuwen, WANG Ping, TIAN Guangwei, ZHENG Fengjie, LYU Li, DU Jiaojiao, ZHANG Jing, ZHUANG Xianghua, CHEN Shihong. Correlation between vitamin D deficiency and depression in patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 51-56.
[9] WANG Yuyu, GAO Li, CHEN Shaohua. Association between cognitive impairment and thyroid function after acute ischemic stroke in 94 patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2020, 58(5): 56-61.
[10] JIN Haiyan, ZHANG Yan, MA Xiaoli, HAN Yu, ZHAO Huichen, LIU Yuantao, ZHANG Yuchao. Expressions of miR-122 and miR-33a in patients with type 2 diabetes complicated with coronary artery disease [J]. Journal of Shandong University (Health Sciences), 2020, 58(3): 94-98.
[11] TANG Bo, SHAO Jing, CUI Jing, SUN Jianping. A mechanism study on the association of type 2 diabetes and high-density lipoprotein [J]. Journal of Shandong University (Health Sciences), 2020, 58(3): 99-106.
[12] TIAN Zhongyan, LI Yuqian, LIU Xiaotian, SHI Yuanyuan, ZHANG Haiqing, ZHANG Xia, QIAN Xinling, YIN Lei, ZHAO Jingzhi, WANG Chongjian. Relationship between PSMD6 gene rs831571 locus polymorphism and the susceptibility of T2DM: a case-control study [J]. Journal of Shandong University (Health Sciences), 2018, 56(7): 51-56.
[13] CHEN Pan, JIANG Chunxia, LEI Yi. Correlation between peripheral Syntaxin 8 expression and chronic inflammation and glucose-lipid metabolism in type 2 diabetes mellitus patients [J]. Journal of Shandong University (Health Sciences), 2018, 56(12): 26-32.
[14] LI Shuai, WANG Yalin, SUN Zhongwen, ZHU Meijia. Expression changes and mechanism of Nod-like receptor protein 3 inflammasome in the cerebral microvascular endothelial cells in type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 6-11.
[15] LIN Dong, GUAN Qingbo. Association of serum testosterone level and non-alcoholic fatty liver disease in male patients with T2DM [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 33-37.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd